[HTML][HTML] Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis
RM Saliba, AM Alousi, J Pidala, M Arora… - … and cellular therapy, 2022 - Elsevier
Post-transplantation cyclophosphamide (PTCy) has been shown to effectively control graft-
versus-host disease (GvHD) in haploidentical (Haplo) transplantations. In this retrospective
registry study, we compared GvHD organ distribution, severity, and outcomes in patients
with GvHD occurring after Haplo transplantation with PTCy GvHD prophylaxis (Haplo/PTCy)
versus HLA-matched unrelated donor transplantation with conventional prophylaxis
(MUD/conventional). We evaluated 2 cohorts: patients with grade 2 to 4 acute GvHD …
versus-host disease (GvHD) in haploidentical (Haplo) transplantations. In this retrospective
registry study, we compared GvHD organ distribution, severity, and outcomes in patients
with GvHD occurring after Haplo transplantation with PTCy GvHD prophylaxis (Haplo/PTCy)
versus HLA-matched unrelated donor transplantation with conventional prophylaxis
(MUD/conventional). We evaluated 2 cohorts: patients with grade 2 to 4 acute GvHD …